Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo to Reconsider 14-Day Limit to Prescriptions
April 12, 2010
- Korosho Cancels 32% of Flu Vaccine Contracts with GSK
April 12, 2010
- Chuikyo to Discuss Drug Pricing System to Deal with 2010 Problem
April 12, 2010
- Diagnostic Criteria for Diabetes to Switch from JDS to NGSP HbA1c Values: Dr Seino
April 12, 2010
- Medical Need Assessed for Only 1/4 of Unapproved Drugs, Indications Listed
April 12, 2010
- US Healthcare Reform to Benefit Drug Industry: Datamonitor
April 12, 2010
- Astellas Signs CDA with OSI
April 12, 2010
- Healthcare Reform to Expand US Drug Market: Mr Wolf of PhRMA
April 12, 2010
- Exforge to Be Novartis' Next Mainstay Product
April 12, 2010
- Expiration Date of OSI Tender Offer Extended to April 23
April 12, 2010
- Eisai Applies for Eribulin in Japan, US, Europe
April 12, 2010
- Takeda Licenses Ferumoxytol from AMAG
April 12, 2010
- Eisai Creates Oncology Area Department
April 12, 2010
- Banyu Applies for Rotavirus Vaccine
April 12, 2010
- Teijin Pharma Licenses TMX-67 to Astellas in China, Hong Kong
April 12, 2010
- Terumo Creates Diabetes Company Aiming at Top Share
April 12, 2010
- GSK's Revolade Approved for Chronic ITP in Europe
April 12, 2010
- Colon Cancer, Center of Attention in Oncology Market in 2010: Dr Gochenauer of Kantar Health
April 12, 2010
- GSK Becomes JCR's Leading Shareholder
April 12, 2010
- Ciprofloxacin DPI Granted Orphan Drug Status in the US
April 12, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…